Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)

被引：0
|
作者：
Park, K. [1 ]
Tan, E. H. [2 ]
Zhang, L. [3 ]
Hirsh, V. [4 ]
O'Byrne, K. [5 ,6 ]
Boyer, M. [7 ]
Yang, J. C-H. [8 ,9 ]
Mok, T. [10 ]
Lee, K. H. [11 ]
Lu, S. [12 ]
Shi, Y. [13 ,14 ]
Kim, S-W. [15 ]
Laskin, J. [16 ]
Kim, D-W. [17 ]
Laurie, S. A. [18 ]
Kolbeck, K. [19 ]
Fan, J. [20 ]
Dodd, N. [21 ]
Maerten, A. [22 ]
Paz-Ares, L. [23 ,24 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Med Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Div Medicial Oncol, Singapore, Singapore
[3] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China
[4] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[5] Princess Alexandra Hosp, Canc Sect, Brisbane, Qld, Australia
[6] Queensland Univ Technol, Brisbane, Qld, Australia
[7] Chris OBrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia
[8] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[9] Natl Taiwan Univ, Taipei, Taiwan
[10] Chinese Univ Hong Kong, Key Lab South China, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[11] Chungbuk Natl Univ Hosp, Med Oncolgy, Cheongju, South Korea
[12] Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[13] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[14] Peking Union Med Coll, Beijing, Peoples R China
[15] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[16] BC Canc Agcy, Med Oncol, Vancouver, BC, Canada
[17] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[18] Ottawa Hosp, Div Med Oncol, Ctr Canc, Ottawa, ON, Canada
[19] Karolinska Univ Hosp Solna, Pulm Dis, Stockholm, Sweden
[20] Boehringer Ingelheim Pharmaceut Inc, Clin Pharmacol, Ridgefield, CT USA
[21] Boehringer Ingelheim Ltd UK, Biostat, Bracknell, Berks, England
[22] Boehringer Ingelheim GmbH & Co KG, TA Oncol, Ingelheim, Germany
[23] Hosp Univ Doce Octubre, Med Oncol, Madrid, Spain
[24] CNIO, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
440O
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
    Hirsh, V.
    Park, K.
    Tan, E. H.
    Zhang, L.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C. H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S. W.
    Laskin, J.
    Kim, D. W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Paz-Ares, L.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S184 - S184
  • [2] Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
    Paz-Ares, L.
    Tan, E. H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T. S. K.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Laurie, S.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm1) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)
    Corral, J.
    Park, K.
    Yang, J. C-H.
    Mok, T.
    Tan, E-H.
    O'Byrne, K.
    Hirsh, V.
    Boyer, M.
    Fan, J.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: LUX-Lung 7
    Hirsh, Vera
    Park, Keunchil
    Tan, Eng-Huat
    Zhang, Li
    O'Byrne, Kenneth
    Boyer, Michael
    Yang, James Chih-Hsin
    Mok, Tony
    Fan, Jean
    Massey, Dan
    Paz-Ares, Luis
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [5] Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC in LUX-Lung (LL) 3, 6 and 7
    Sequist, L.
    Wu, Y-L.
    Schuler, M.
    Kato, T.
    Yang, J. C-H.
    Tanaka, H.
    Hida, T.
    Lu, S.
    Park, K.
    Laurie, S.
    Bennouna, J.
    Sibilot, D. Moro
    Maerten, A.
    Peil, B.
    Ehrnrooth, E.
    Yamamoto, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
    Schuler, M.
    Tan, E-H.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T. S. K.
    Hirsh, V.
    Yang, J. C-H.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Arvis, C. Dubos
    Kolbeck, K.
    Massey, D.
    Fan, J.
    Paz-Ares, L.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC in LUX-Lung 3, 6 and 7
    Sequist, L. V.
    Wu, Y.
    Schuler, M.
    Kato, T.
    Yang, J. C.
    Tanaka, H.
    Hida, T.
    Lu, S.
    Park, K.
    Paz-Ares, L.
    Laurie, S.
    Bennouna, J.
    Sibilot, D. Moro
    Maerten, A.
    Tang, W.
    Ehrnrooth, E.
    Yamamoto, N.
    Nakagawa, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1572 - S1572
  • [8] First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7
    Park, Keunchil
    Tan, Eng Huat
    Zhang, Li
    Hirsh, Vera
    O'Byrne, Ken
    Boyer, Michael
    Yang, James Chih-Hsin
    Mok, Tony
    Lee, Ki Hyeong
    Lu, Shun
    Shi, Yuankai
    Kim, Sang-We
    Laskin, Janessa
    Kim, Dong-Wan
    Laurie, Scott
    Kolbeck, Karl
    Fan, Jean
    Dodd, Nigel
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S335 - S336
  • [9] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    Paz-Ares, L.
    Tan, E. -H.
    O'Byrne, K.
    Zhang, L.
    Hirsh, V.
    Boyer, M.
    Yang, J. C. -H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Lee, D. H.
    Laskin, J.
    Kim, D. -W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Marten, A.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 270 - 277
  • [10] First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).
    Hirsh, Vera
    Yang, James Chih-Hsin
    Tan, Eng-Huat
    O'Byrne, Ken
    Zhang, Li
    Boyer, Michael J.
    Mok, Tony
    Lee, Ki Hyeong
    Lu, Shun
    Shi, Yuankai
    Kim, Sang-We
    Laskin, Janessa J.
    Kim, Dong-Wan
    Arvis, Catherine Dubos
    Kolbeck, Karl
    Schuler, Martin H.
    Massey, Dan
    Maerten, Angela
    Paz-Ares, Luis
    Park, Keunchil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345